NXTC – Nextcure Inc
NextCure, Inc.NXTC
$0.4505Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,636,615.00
EPSttm : -1.77
NextCure, Inc.
$0.4505
0.11%$0.0005Float Short %
1.22
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.01
EPS Last/This Y
0.4
EPS This/Next Y
0.16
Price
0.46
Target Price
3
Analyst Recom
1
Performance Q
-15.21
Relative Volume
0.66
Beta
1.07
Ticker: NXTC
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | NXTC | 0.4994 | 0.00 | 0.00 | 41 |
| 2025-06-03 | NXTC | 0.474 | 0.00 | 0.00 | 41 |
| 2025-06-04 | NXTC | 0.478 | 0.00 | 0.00 | 43 |
| 2025-06-05 | NXTC | 0.4976 | 0.00 | 0.00 | 43 |
| 2025-06-06 | NXTC | 0.5 | 0.00 | 0.00 | 43 |
| 2025-06-09 | NXTC | 0.5401 | 0.00 | 0.00 | 43 |
| 2025-06-10 | NXTC | 0.543 | 0.00 | 0.00 | 46 |
| 2025-06-11 | NXTC | 0.6151 | 0.00 | 0.00 | 49 |
| 2025-06-12 | NXTC | 0.6503 | 0.00 | 0.00 | 49 |
| 2025-06-13 | NXTC | 0.6848 | 0.00 | 0.00 | 49 |
| 2025-06-16 | NXTC | 0.505 | 0.00 | 0.00 | 59 |
| 2025-06-17 | NXTC | 0.4555 | 0.00 | 0.00 | 62 |
| 2025-06-18 | NXTC | 0.459 | 0.00 | 0.00 | 62 |
| 2025-06-20 | NXTC | 0.4816 | 0.00 | 0.00 | 62 |
| 2025-06-23 | NXTC | 0.461 | 0.00 | 0.00 | 42 |
| 2025-06-24 | NXTC | 0.48 | 0.00 | 0.00 | 42 |
| 2025-06-25 | NXTC | 0.46 | 0.00 | 0.00 | 43 |
| 2025-06-26 | NXTC | 0.4604 | 0.00 | 0.00 | 43 |
| 2025-06-27 | NXTC | 0.46 | 0.00 | 0.00 | 43 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | NXTC | 0.48 | 30.0 | - | -1.58 |
| 2025-06-03 | NXTC | 0.47 | 30.0 | - | -1.58 |
| 2025-06-04 | NXTC | 0.47 | 30.0 | - | -1.58 |
| 2025-06-05 | NXTC | 0.50 | 30.0 | - | -1.58 |
| 2025-06-06 | NXTC | 0.49 | 30.0 | - | -1.58 |
| 2025-06-09 | NXTC | 0.53 | 30.0 | - | -1.58 |
| 2025-06-10 | NXTC | 0.55 | 30.0 | - | -1.58 |
| 2025-06-11 | NXTC | 0.62 | 30.0 | - | -1.58 |
| 2025-06-12 | NXTC | 0.65 | 30.0 | - | -1.58 |
| 2025-06-13 | NXTC | 0.70 | 30.0 | - | -1.58 |
| 2025-06-16 | NXTC | 0.50 | 30.0 | - | -1.58 |
| 2025-06-17 | NXTC | 0.46 | 30.0 | - | -1.58 |
| 2025-06-18 | NXTC | 0.45 | 30.0 | - | -1.58 |
| 2025-06-20 | NXTC | 0.47 | 30.0 | - | -1.58 |
| 2025-06-23 | NXTC | 0.46 | 30.0 | - | -1.58 |
| 2025-06-24 | NXTC | 0.47 | 30.0 | - | -1.58 |
| 2025-06-25 | NXTC | 0.45 | 30.0 | - | -1.58 |
| 2025-06-26 | NXTC | 0.46 | 30.0 | - | -1.58 |
| 2025-06-27 | NXTC | 0.46 | 30.0 | - | -1.58 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-03 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-04 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-05 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-06 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-09 | NXTC | 0.00 | -7.22 | 1.48 |
| 2025-06-11 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-12 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-13 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-16 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-17 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-18 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-19 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-20 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-24 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-25 | NXTC | 0.00 | -7.22 | 0.33 |
| 2025-06-26 | NXTC | 0.00 | -7.22 | 1.22 |
| 2025-06-27 | NXTC | 0.00 | -7.22 | 1.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.39
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.39
Insider Transactions
Institutional Transactions
-7.22
Beta
1.07
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
5
Growth Score
20
Sentiment Score
41
Actual DrawDown %
98
Max Drawdown 5-Year %
-98.8
Target Price
3
P/E
Forward P/E
PEG
P/S
P/B
0.23
P/Free Cash Flow
EPS
-1.77
Average EPS Est. Cur. Y
-1.58
EPS Next Y. (Est.)
-1.43
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.66
Return on Equity vs Sector %
-112.6
Return on Equity vs Industry %
-94.7
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
NextCure, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading